{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:20:05Z","timestamp":1789402805727,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"vor","delay-in-days":136,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.vaccine.2022.02.058","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T16:28:53Z","timestamp":1646929733000},"page":"A70-A78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S1","title":["Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal"],"prefix":"10.1016","volume":"41","author":[{"given":"Vachagan","family":"Harutyunyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad","family":"Quddus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Pallansch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Zipursky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Ottosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vertefeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.02.058_b0005","unstructured":"World Health Organization. World Health Assembly. Global eradication of poliomyelitis by the year 2000 (resolution 41.28). 1988 [cited 2021 June 29]; Available from: https:\/\/polioeradication.org\/wp-content\/uploads\/2016\/07\/19880513_resolution-2.pdf."},{"key":"10.1016\/j.vaccine.2022.02.058_b0010","unstructured":"Centers for Disease Control and Prevention. Our progress against polio. 2021 [cited 2021 June 29]; Available from: https:\/\/www.cdc.gov\/polio\/progress\/index.htm."},{"key":"10.1016\/j.vaccine.2022.02.058_b0015","unstructured":"World Health Organization. Global eradication of wild poliovirus type 2 declared. 2015 [cited 2021 June 21]; Available from: https:\/\/polioeradication.org\/news-post\/global-eradication-of-wild-poliovirus-type-2-declared\/."},{"key":"10.1016\/j.vaccine.2022.02.058_b0020","unstructured":"World Health Organization. Oral Polio Vaccine Switch On Track for April 2016. 2015 [cited 2021 June 29]; Available from: https:\/\/polioeradication.org\/news-post\/oral-polio-vaccine-switch-on-track-for-april-2016\/."},{"key":"10.1016\/j.vaccine.2022.02.058_b0025","unstructured":"World Health Organization. World Health Assembly, Poliomyelitis: mechanism for management of potential risks to eradication (resolution 61.1). 2008 [cited 2021 June 29]; Available from: https:\/\/polioeradication.org\/wp-content\/uploads\/2016\/07\/WHA61_Resolution_English.pdf."},{"issue":"20","key":"10.1016\/j.vaccine.2022.02.058_b0030","first-page":"284","article-title":"Access to life-saving vaccines during outbreaks: a spotlight on governance","volume":"93","author":"Nguyen","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2022.02.058_b0035","unstructured":"World Health Organization. OPV Cessation: Plan for tOPV Campaigns Immediately Prior to tOPV to bOPV Switch. 2014 [cited 2021 June 29]; Available from: https:\/\/www.who.int\/immunization\/sage\/meetings\/2014\/october\/5_Plan_for_tOPV_Campaigns_v21.pdf."},{"issue":"8","key":"10.1016\/j.vaccine.2022.02.058_b0040","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/14760584.2018.1506333","article-title":"Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine","volume":"17","author":"Duintjer Tebbens","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2022.02.058_b0045","unstructured":"World Health Organization. Polio Post-Certification Strategy: A risk mitigation strategy for a polio-free world. 2018 [cited 2021 June 29]; Available from: https:\/\/polioeradication.org\/wp-content\/uploads\/2018\/04\/polio-post-certification-strategy-20180424-2.pdf."},{"key":"10.1016\/j.vaccine.2022.02.058_b0050","unstructured":"World Health Organization. Poliomyelitis: intensification of the global eradication initiative. Report by the Secretariat (A67\/38). 2014 [cited 2021 June 29]; Available from: https:\/\/polioeradication.org\/wp-content\/uploads\/2016\/07\/A67_38-en.pdf."},{"key":"10.1016\/j.vaccine.2022.02.058_b0055","unstructured":"World Health Organization. Poliomyelitis. Resolution WHA68.3. 2015 [cited 2021 June 29]; Available from: https:\/\/polioeradication.org\/wp-content\/uploads\/2016\/07\/A68_R3-en.pdf."},{"key":"10.1016\/j.vaccine.2022.02.058_b0060","unstructured":"World Health Organization. WHO Global Action Plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use: GAPIII. 2015 [cited 2021 June 29]; Available from: https:\/\/polioeradication.org\/wp-content\/uploads\/2016\/12\/GAPIII_2014.pdf."},{"key":"10.1016\/j.vaccine.2022.02.058_b0065","unstructured":"World Health Organization. Guidance to minimize risks for facilities collecting, handling or storing materials potentially infectious for polioviruses. 2018 [cited 2021 June 29]; Available from: https:\/\/polioeradication.org\/wp-content\/uploads\/2018\/06\/polio-containment-guidance-for-non-poliovirus-facilities-20180614-en.pdf."},{"key":"10.1016\/j.vaccine.2022.02.058_b0070","unstructured":"World Health Organization. Operational Framework for Monovalent Oral Poliovirus Type 2 (mOPV2) deployment and replenishment (during the endgame period). 2014 [cited 2021 June 29]; Available from: https:\/\/www.who.int\/immunization\/sage\/meetings\/2014\/october\/4_Polio_mOPV2_stockpile_v4_09_10_2014.pdf."},{"key":"10.1016\/j.vaccine.2022.02.058_b0075","unstructured":"World Health Organization. GPEI Strategy for the Response to cVDPV2: 2020-2021. 2020 [cited 2021 June 29]; Available from: https:\/\/polioeradication.org\/wp-content\/uploads\/2021\/03\/GPEI-cVDPV2-nOPV2-Factsheet-20210312-EN.pdf."},{"key":"10.1016\/j.vaccine.2022.02.058_b0080","unstructured":"World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, 31 March\u20131 April 2020: conclusions and recommendations. Wkly Epidemiol Rec, 2020; 95(22): 241\u201356."},{"key":"10.1016\/j.vaccine.2022.02.058_b0085","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12879-016-1465-7","article-title":"Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"10193","key":"10.1016\/j.vaccine.2022.02.058_b0090","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(19)31279-6","article-title":"The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study","volume":"394","author":"Van Damme","year":"2019","journal-title":"Lancet"},{"issue":"10268","key":"10.1016\/j.vaccine.2022.02.058_b0095","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(20)32541-1","article-title":"Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials","volume":"397","author":"De Coster","year":"2021","journal-title":"Lancet"},{"issue":"10268","key":"10.1016\/j.vaccine.2022.02.058_b0100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(20)32540-X","article-title":"Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials","volume":"397","author":"S\u00e1ez-Llorens","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2022.02.058_b0105","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/risa.13622","article-title":"Updated characterization of outbreak response strategies for 2019\u20132029: impacts of using a novel type 2 oral poliovirus vaccine strain","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2022.02.058_b0110","unstructured":"World Health Organization. Recommendation for an emergency use listing (EUL) of novel oral polio vaccine type 2 (nOPV2) submitted by PT Biofarma (Persero). 2020 [cited 2021 June 29]; Available from: https:\/\/extranet.who.int\/pqweb\/sites\/default\/files\/documents\/nOPV2_EUL_recommendation.pdf."},{"issue":"4","key":"10.1016\/j.vaccine.2022.02.058_b0115","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1539-6924.2012.01891.x","article-title":"Modeling population immunity to support efforts to end the transmission of live polioviruses","volume":"33","author":"Thompson","year":"2013","journal-title":"Risk Anal"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22002043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22002043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:24:38Z","timestamp":1759404278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22002043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":23,"alternative-id":["S0264410X22002043"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.058","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}